bioRxiv Science⌕ Search

Biology subjects

Landau, O.

Publications and source records attributed to Landau, O..

2 recordsLinked to original sources

TCUP: An Open Access Tool to Predict Tissue of Origin and Cancer of Unknown Primary (CUP)

IntroductionCancer of unknown primary (CUP) remains a major diagnostic hurdle, compromising therapies that depend on accurately identifying tissue of origin. We present TCUP, an ensemble learning framework that combines Contrastive Autoencoders (CAE) and Siamese Neural Networks (SNN) with base classifiers and a meta-learning layer to classify and interpret CUP, adding biological insight through Monte-Carlo ablations. MethodsGene-expression data from TCGA (tumour), GTEx (normal), and the Genome Sciences Centre (metastatic) were imputed, log-transformed, and SMOTE-balanced. A SNN and CAE learned pairwise and reconstruction embeddings. Multiple base classifiers (e.g., SVM, Random Forest) generated meta-features, which a meta-learner combined for final prediction. Monte-Carlo ablation iterations were performed to assess gene-level importance. ResultsTCUP achieved 98.3 % accuracy (F1 = 98.3) across all tissues. In metastatic BRCA, COAD, and PAAD it reached 86.7 % accuracy. Ablation highlighted 79 key contributors, including established tumour suppressors NKX6-1 and SOX30 and the less-studied SYTL1. PCA confirmed clearer separation in embedded space. ConclusionTCUP delivers high tissue-of-origin accuracy and CUP assignment while providing interpretable gene importance that clarifies tissue differences and metastatic drivers. By integrating advanced embeddings with systematic ablation TCUP supplies an accessible framework to advance CUP research and, ultimately, improve clinical outcomes. TCUP is freely available at https://fohs.bgu.ac.il/rubinlab/TCUP/

bioinformatics↗

OptiRanker: an Advanced Tool for Simulation and Comparative Analysis of Drug Prioritization Algorithms in in-Vivo Trials

A critical challenge in personalized medicine is identifying the optimal drug treatment for individual patients based on their unique biological profiles. While recent advancements have led to a surge in drug prioritization algorithms utilizing patient omics data, including regression, classification, multiple kernel learning, deep learning, and AI-based methods, objective validation remains essential to discern their effectiveness. This study introduces" OptiRanker," an innovative statistical framework designed to simulate and optimize the in vivo validation of these drug prioritization algorithms by ranking their predictive accuracy across varied conditions. OptiRanker not only mimics algorithmic predictions but also integrates them into ranked datasets, enabling the optimal selection of test subjects and drugs for trial setups. By providing a rigorous evaluation subset for ranking and comparison of high- and low-performing algorithms, OptiRanker facilitates the design of cost-effective in vivo trials tailored to efficiently assess predictive capability. This addresses a key bottleneck in personalized medicine: achieving a robust, scalable validation of computational models that can accelerate the clinical translation of promising algorithms. The efficient ranking provided by OptiRanker has the potential to advance personalized treatment strategies, ultimately leading to more effective, individualized patient care. The Python code for OptiRanker is available at the following GitHub repository: https://github.com/OhadLandau/OptiRanker.

bioinformatics↗